anti-CD72 CAR-T cell therapy

Anti-CD72 CAR-T cell therapy is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target CD72, a membrane protein expressed on B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoma. Developed as a potential treatment for patients who relapse after CD19-directed therapies, this scFv-based immunotherapy utilizes a second-generation CAR construct. Research has identified CD72 as a promising target due to its homogenous expression in B-cell tumors and restricted expression in normal tissues. Preclinical studies have demonstrated that constructs utilizing CD28 costimulatory domains (e.g., CD72-28x3-3z) exhibit potent cytotoxicity against CD72-expressing target cells, including those resistant to CD19 CAR-T therapy.

Other names

scFv-based anti-CD72 CAR-T cell therapyCD72-directed CAR-T cell therapyCD-72-directed CAR-T cell therapyCD 72-directed CAR-T cell therapyCD72-28x3-3zCD-72-28x3-3zCD 72-28x3-3z